var data={"title":"Lisdexamfetamine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Lisdexamfetamine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/321396?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=lisdexamfetamine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Lisdexamfetamine: Patient drug information&quot;</a> and <a href=\"topic.htm?path=lisdexamfetamine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Lisdexamfetamine: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709015\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Abuse and dependence:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">CNS stimulants (amphetamines and methylphenidate-containing products), including lisdexamfetamine,  have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24520558\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Vyvanse</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10170113\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Vyvanse</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4425750\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Central Nervous System Stimulant</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6126904\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Prior to treatment, assess for presence of cardiac disease and assess for risk of abuse.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Attention-deficit/hyperactivity disorder (ADHD):</b> Oral: Initial: 30 mg once daily in the morning; may increase in increments of 10 mg or 20 mg at weekly intervals until optimal response is obtained; maximum: 70 mg/day. <b>Note:</b> Individualize dosage based on patient need and response to therapy. Administer at the lowest effective dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Binge eating disorder:</b> Oral: Initial: 30 mg once daily in the morning; may titrate in increments of 20 mg at weekly intervals to target dose of 50 to 70 mg once daily (maximum: 70 mg/day); discontinue use if binge eating does not improve.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4425789\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=lisdexamfetamine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Lisdexamfetamine: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Attention-deficit/hyperactivity disorder (ADHD): </b> <b>Note: </b> Prior to treatment, assess for presence of cardiac disease and assess for risk of abuse. Individualize dosage based on patient need and response to therapy. Administer at the lowest effective dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Children &ge;6 years and Adolescents: Oral: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49115760\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing; initiate dose at the low end of the dosing range.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25802880\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">GFR &ge;30 mL/minute/1.73 m<sup>2</sup>: There are no dosage adjustments provided in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">GFR 15 to &lt;30 mL/minute/1.73 m<sup>2</sup>: Maximum dose: 50 mg/day.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">GFR &lt;15 mL/minute/1.73 m<sup>2</sup>: Maximum dose: 30 mg/day.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ESRD requiring hemodialysis: Maximum dose: 30 mg/day; lisdexamfetamine and dextroamphetamine are not dialyzable.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25802881\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24520559\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral, as dimesylate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vyvanse: 10 mg, 20 mg, 30 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c yellow #6 (sunset yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vyvanse: 40 mg, 50 mg, 60 mg [contains brilliant blue fcf (fd&amp;c blue #1)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vyvanse: 70 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c yellow #6 (sunset yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Chewable, Oral, as dimesylate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vyvanse: 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4425748\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21124159\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4425744\" class=\"block csi drugH1Div\"><span class=\"drugH1\">Controlled Substance</span>\n    <p style=\"text-indent:0em;display:inline\">C-II</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7874689\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Vyvanse: <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021977s044lbl.pdf#page=37&amp;token=cOgd1yM5lxH0Ju0zGax+VJGQl5ms1CGOoaXCHJbUXjb5ml9eiu1euE9klz/S86mnLb465eNUoceI4wvyAnF8Jw/B5YFQoyUP2AdFGPzs+kZzikMBEaQWkp9E/Yri7has&amp;TOPIC_ID=10143\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021977s044lbl.pdf#page=37</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4425790\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Administer in the morning without regard to meals; avoid afternoon doses because of potential for insomnia. Do not take less than one capsule or chewable tablet per day; a single dose should not be divided.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capsules: Swallow capsule whole, do not chew. Capsule may be opened and the entire contents mixed with water, yogurt, or orange juice; stir until dispersed completely and consume the entire mixture immediately; do not store mixture. The active ingredient dissolves completely once dispersed; however, a film containing the inactive ingredients may remain in the glass or container once the mixture is consumed.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chewable tablets: Chew thoroughly before swallowing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4425751\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Attention-deficit/hyperactivity disorder:</b> Treatment of attention-deficit/hyperactivity disorder (ADHD).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Binge eating disorder:</b> Treatment of moderate to severe binge eating disorder in adults.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4425741\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Vyvanse may be confused with Glucovance, Visanne, ViVAXIM, Vytorin, Vivactil</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4425761\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Insomnia (13% to 27%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Xerostomia (adults: 26% to 36%; children and adolescents: 4% to 5%), upper abdominal pain (children: 12%; adults: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Increased heart rate (adults: 2% to 7%), increased blood pressure (adults: 3%), palpitations (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Irritability (children: 10%), anxiety (adults: 5% to 6%), jitteriness (adults: 4% to 6%), dizziness (children: 5%), agitation (adults: 3%), emotional lability (children: 3%), restlessness (adults: 2% to 3%), drowsiness (children: 2%), increased energy (adults: 2%), nightmares (adults: 2%), paresthesia (adults: 2%), tics (children: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Hyperhidrosis (adults: 3% to 4%), skin rash (children: 3%), pruritus (adults: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Weight loss (children and adolescents: 9%; adults: 3% to 4%), decreased libido (adults: &lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Vomiting (children: 9%; adults: 2%), diarrhea (adults: 7%), nausea (6% to 7%), constipation (adults: 6%), anorexia (2% to 5%), gastroenteritis (adults: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Erectile dysfunction (adults: 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Tremor (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Dyspnea (adults: 2%), oropharyngeal pain (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (children: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Outbursts of anger, paranoia, talkativeness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Accommodation disturbance, aggressive behavior, alopecia, anaphylaxis, angioedema, blurred vision, bruxism, cardiomyopathy, chest pain, decreased linear skeletal growth rate, depression, dermatillomania, diplopia, dysgeusia, dyskinesia, excoriation, frequent erections, hallucination, headache, hepatitis (eosinophilic), hypersensitivity, mania, mydriasis, peripheral vascular insufficiency, prolonged erection, psychotic reaction, Raynaud phenomenon, seizure, Stevens-Johnson syndrome, urticaria</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4425757\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to amphetamine products or any component of the formulation; concurrent use of MAO inhibitor, or within 14 days of the last MAO inhibitor dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling: </i>Additional contraindications (not in US labeling): Known hypersensitivity or idiosyncrasy to sympathomimetic amines; advanced arteriosclerosis; symptomatic cardiovascular disease; moderate-to-severe hypertension; hyperthyroidism; glaucoma; agitated states; history of drug abuse</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4425758\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular events: Stimulant use has been associated with serious cardiovascular events including sudden death in patients with preexisting structural cardiac abnormalities or other serious heart problems (sudden death in children and adolescents; sudden death, stroke and MI in adults). These products should be avoided in patients with known serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems that could increase the risk of sudden death. Patients should be carefully evaluated for these cardiac disorders prior to initiation of therapy. Patients who develop exertional chest pain, unexplained syncope, or arrhythmias during therapy should be evaluated promptly. CNS stimulants may increase heart rate (mean increase: 3 to 6 bpm) and blood pressure (mean increase: 2 to 4 mm Hg); monitor all patients for tachycardia and hypertension.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS effects: Amphetamines may impair the ability to engage in potentially hazardous activities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Hypersensitivity reactions, including anaphylaxis, Stevens-Johnson syndrome, angioedema, and urticaria have been observed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Peripheral vasculopathy: Stimulants are associated with peripheral vasculopathy, including Raynaud phenomenon; signs/symptoms are usually mild and intermittent, and generally improve with dose reduction or discontinuation. Digital ulceration and/or soft tissue breakdown have been observed rarely; monitor for digital changes during therapy and seek further evaluation (eg, rheumatology) if necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Visual disturbance: Difficulty in accommodation and blurred vision has been reported with the use of stimulants.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Psychiatric disorders: Use with caution in patients with preexisting psychosis or bipolar disorder (may induce mixed/manic episode). May exacerbate symptoms of behavior and thought disorder in psychotic patients; new onset psychosis or mania may occur in children or adolescents with stimulant use. Patients should be screened for bipolar disorder and risk factors for developing mania prior to treatment; consider discontinuation if such symptoms (eg, delusional thinking, hallucinations, or mania) occur. May be associated with aggressive behavior or hostility (causal relationship not established); monitor for development or worsening of these behaviors.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tourette syndrome/tics: Use with caution in patients with Tourette syndrome or other tic disorders. Stimulants may exacerbate tics (motor and phonic) and Tourette syndrome; however, evidence demonstrating increased tics is limited. Evaluate for tics and Tourette syndrome prior to therapy initiation (AACAP [Murphy 2013]; Pliszka 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Serotonin syndrome: Potentially life-threatening serotonin syndrome (SS) may occur when lisdexamfetamine is used in combination with other serotonergic agents (eg, selective serotonin reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, St. John's wort, tryptophan), agents that impair metabolism of serotonin (eg, monoamine oxidase inhibitors) or CYP2D6 inhibitors that impair metabolism of lisdexamfetamine. Concomitant use with monoamine oxidase inhibitors is contraindicated. If concomitant use of lisdexamfetamine with serotonergic drugs or CYP2D6 inhibitors is indicated, initiate lisdexamfetamine at a low dose and monitor patient closely for signs and symptoms of SS. Discontinue treatment (and any concomitant serotonergic agent) immediately if signs/symptoms arise.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use caution in this age group due to CNS stimulant adverse effects.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Appetite suppression may occur; particularly in children. Use of stimulants has been associated with weight loss and slowing of growth rate; monitor growth rate and weight during treatment. Treatment interruption may be necessary in patients who are not increasing in height or gaining weight as expected.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Abuse/misuse/diversion: <b>[US Boxed Warning]: Has high potential for abuse and dependence; assess for abuse potential prior to use and monitor for signs of abuse and dependence while on therapy.</b> Use with caution in patients with a history of ethanol or drug abuse. Prescriptions should be written for the smallest quantity consistent with good patient care to minimize possibility of overdose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; ADHD treatment: Appropriate use: Recommended to be used as part of a comprehensive treatment program for attention deficit disorders.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Weight loss: Appropriate use: Not indicated or recommended for weight loss; safety and efficacy not established for treatment of obesity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Discontinuation of therapy: Abrupt discontinuation following high doses or for prolonged periods may result in symptoms for withdrawal (eg, depression, extreme fatigue).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299610\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4425767\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=10143&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acebrophylline: May enhance the stimulatory effect of CNS Stimulants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alkalinizing Agents: May decrease the excretion of Amphetamines.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ammonium Chloride: May decrease the serum concentration of Amphetamines. This effect is likely due to an enhanced excretion of amphetamines in the urine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antacids: May decrease the excretion of Amphetamines.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antihistamines: Amphetamines may diminish the sedative effect of Antihistamines. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antihypertensive Agents: Amphetamines may diminish the antihypertensive effect of Antihypertensive Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents: May diminish the stimulatory effect of Amphetamines.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ascorbic Acid: May decrease the serum concentration of Amphetamines.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BuPROPion: May enhance the neuroexcitatory and/or seizure-potentiating effect of Agents With Seizure Threshold Lowering Potential.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics.<b> Exceptions: </b>Cannabidiol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Carbonic Anhydrase Inhibitors: May decrease the excretion of Amphetamines.<b> Exceptions: </b>Brinzolamide; Dorzolamide.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2D6 Inhibitors (Moderate): May increase the serum concentration of Amphetamines.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2D6 Inhibitors (Strong): May increase the serum concentration of Amphetamines.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ethosuximide: Amphetamines may diminish the therapeutic effect of Ethosuximide. Amphetamines may decrease the serum concentration of Ethosuximide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal Acidifying Agents: May decrease the serum concentration of Amphetamines.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ioflupane I 123: Amphetamines may diminish the diagnostic effect of Ioflupane I 123. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iohexol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iohexol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iohexol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iomeprol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iopamidol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid.  Specific dose adjustment recommendations are not presently available.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lithium: May diminish the stimulatory effect of Amphetamines.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methenamine: May decrease the serum concentration of Amphetamines. This effect is likely due to an enhanced excretion of amphetamines in the urine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: May enhance the hypertensive effect of Amphetamines. While linezolid and tedizolid may interact via this mechanism, management recommendations differ from other monoamine oxidase inhibitors.  Refer to monographs specific to those agents for details.<b> Exceptions: </b>Linezolid; Tedizolid.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Fluoride (with ADE): May decrease the serum concentration of Amphetamines. More specifically, the ascorbic acid (vitamin C) in many multivitamins may decrease amphetamine concentrations.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Amphetamines.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with AE, No Iron): May decrease the serum concentration of Amphetamines. Specifically, vitamin C may impair absorption of amphetamines.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: Amphetamines may enhance the analgesic effect of Opioid Analgesics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PHENobarbital: Amphetamines may decrease the serum concentration of PHENobarbital. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: Amphetamines may decrease the serum concentration of Phenytoin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tricyclic Antidepressants: May enhance the stimulatory effect of Amphetamines. Tricyclic Antidepressants may also potentiate the cardiovascular effects of Amphetamines.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Urinary Acidifying Agents: May decrease the serum concentration of Amphetamines.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4425771\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">High-fat meal prolongs T<sub>max</sub> by ~1 hour. Management: Administer without regard to meals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4425753\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Lisdexamfetamine is converted to dextroamphetamine. The majority of human data is based on illicit amphetamine/methamphetamine exposure and not from therapeutic maternal use (Golub 2005). Use of amphetamines during pregnancy may lead to an increased risk of premature birth and low birth weight; newborns may experience symptoms of withdrawal. Behavioral problems may also occur later in childhood (LaGasse 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4425756\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">The majority of human data is based on illicit amphetamine/methamphetamine exposure and not from therapeutic maternal use (Golub 2005). Amphetamines are excreted into breast milk and use may decrease milk production. Increased irritability, agitation, and crying have been reported in nursing infants (ACOG 2011). Due to the potential for adverse reactions in a nursing infant, breast-feeding is not recommended by the manufacturer.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4425792\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Cardiac evaluation should be completed on any patient who develops exertional chest pain, unexplained syncope, and any symptom of cardiac disease during treatment with stimulants. Thoroughly evaluate for cardiovascular risk and the presence of (and family history of) cardiac disease, cardiac arrhythmias, or Marfan syndrome prior to initiating treatment. Monitor heart rate, blood pressure, and consider obtaining ECG prior to initiation (Vetter 2008). Monitor growth (height and weight) in children; CNS activity in all patients; signs of peripheral vasculopathy (eg, digital changes); behavioral changes. Assess for risk of abuse prior to prescribing and signs of misuse, abuse, or addiction throughout treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4425785\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">The exact mechanism of lisdexamfetamine in ADHD and binge eating disorder is not known. Lisdexamfetamine dimesylate is a prodrug that is converted to the active component dextroamphetamine (a noncatecholamine, sympathomimetic amine). Amphetamines are noncatecholamine, sympathomimetic amines that cause release of catecholamines (primarily dopamine and norepinephrine) from their storage sites in the presynaptic nerve terminals.  A less significant mechanism may include their ability to block the reuptake of catecholamines by competitive inhibition.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4425774\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration of action: 8 to 14 hours (Jain 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Rapid</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Metabolized in the blood by hydrolytic activity of red blood cells to dextroamphetamine and l-lysine; does not undergo CYP mediated metabolism</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Lisdexamfetamine: &lt;1 hour; Dextroamphetamine: 10 to 13 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Capsule: T<sub>max</sub>: Lisdexamfetamine: Children 6 to 12 years: 1 hour (fasting); Adults: ~1 hour; Dextroamphetamine: Children 6 to 12 years: 3.5 hours (fasting); Adults: 3.8 hours (fasting), 4.7 hours (after a high-fat meal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Chewable tablet: T<sub>max</sub>: Lisdexamfetamine: 1 hour (fasting); Dextroamphetamine: 3.9 to 4.4 hours (fasting); 4.9 hours (after a high-fat meal)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (96%, 42% as amphetamine-related compounds, 2% as lisdexamfetamine, 25% hippuric acid); feces (minimal)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5989464\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Vyvanse Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $1,179.96</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (100): $1,179.96</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (100): $1,179.96</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (100): $1,179.96</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (100): $1,179.96</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60 mg (100): $1,179.96</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">70 mg (100): $1,179.96</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Chewable</b> (Vyvanse Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $1,179.96</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (100): $1,179.96</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (100): $1,179.96</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (100): $1,179.96</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (100): $1,179.96</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60 mg (100): $1,179.96</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22059480\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Elvanse (AT, CH, CZ, DE, DK, ES, FI, GB, NO, PT, SE);</li>\n      <li>Samexid (CL);</li>\n      <li>Tyvense (IE);</li>\n      <li>Venvanse (BR);</li>\n      <li>Vyvanse (AU, BB, IL)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG) Committee Opinion: No. 479, &ldquo;Methamphetamine Abuse in Women of Reproductive Age,&rdquo; <i>Obstet Gynecol</i>, 2011, 117(3):751-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lisdexamfetamine-drug-information/abstract-text/21343793/pubmed\" target=\"_blank\" id=\"21343793\">21343793</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Canadian Attention Deficit Hyperactivity Disorder Resource Alliance (CADDRA): &quot;Canadian ADHD Practice Guidelines,&quot; Third Edition, Toronto, ON: CADDRA, 2011. Available at http://caddra.ca/cms4/pdfs/caddraGuidelines2011.pdf. Last accessed on July 12, 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chiang WK, &ldquo;Amphetamines,&rdquo; <i>Goldfrank's Toxicologic Emergencies</i>, 8th edition, Flomenbaum NE, Goldfrank LR, Hoffman RS, et al, eds, New York: The McGraw-Hill Companies, Inc, 2006, 1119.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cooper WO, Habel LA, Sox CM, et al, &ldquo;ADHD Drugs and Serious Cardiovascular Events in Children and Young Adults,&rdquo; <i>N Engl J Med</i>, 2011, 365(20):1896-904.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lisdexamfetamine-drug-information/abstract-text/22043968/pubmed\" target=\"_blank\" id=\"22043968\">22043968</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fratto G, Manzon L. Use of psychotropic drugs and associated dental diseases. <i>Int J Psychiatry Med.</i> 2014;48(3):185-197.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lisdexamfetamine-drug-information/abstract-text/25492713/pubmed\" target=\"_blank\" id=\"25492713\">25492713</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Golub M, Costa L, Crofton K, et al, &quot;NTP-CERHR Expert Panel Report on the Reproductive and Developmental Toxicity of Amphetamine and Methamphetamine,&quot; <i>Birth Defects Res B Dev Reprod Toxicol</i>, 2005, 74(6):471-584.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lisdexamfetamine-drug-information/abstract-text/16167346/pubmed\" target=\"_blank\" id=\"16167346\">16167346</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Habel LA, Cooper WO, Sox CM, et al, &ldquo;ADHD Medications and Risk of Serious Cardiovascular Events in Young and Middle-Aged Adults,&rdquo; 2011, <i>JAMA</i>, 306(24):2673-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lisdexamfetamine-drug-information/abstract-text/22161946/pubmed\" target=\"_blank\" id=\"22161946\">22161946</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jain R, Jain S, Montano CB. Addressing diagnosis and treatment gaps in adults with attention-deficit/hyperactivity disorder. <i>Prim Care Companion CNS Disord</i>. 2017;19(5). pii: 17nr02153. doi: 10.4088/PCC.17nr02153.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lisdexamfetamine-drug-information/abstract-text/28906602/pubmed\" target=\"_blank\" id=\"28906602\">28906602</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    LaGasse LL, Derauf C, Smith LM, et al, &quot;Prenatal Methamphetamine Exposure and Childhood Behavior Problems at 3 and 5 Years of Age,&quot; <i>Pediatrics</i>, 2012, 129(4):681-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lisdexamfetamine-drug-information/abstract-text/22430455/pubmed\" target=\"_blank\" id=\"22430455\">22430455</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Murphy TK, Lewin AB, Storch EA, Stock S; American Academy of Child and Adolescent Psychiatry (AACAP) Committee on Quality Issues (CQI). Practice parameter for the assessment and treatment of children and adolescents with tic disorders. <i>J Am Acad Child Adolesc Psychiatry</i>. 2013;52(12):1341-1359.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lisdexamfetamine-drug-information/abstract-text/24290467/pubmed\" target=\"_blank\" id=\"24290467\">24290467</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Institute for Health and Clinical Excellence (NICE), National Collaborating Centre for Mental Health , &ldquo;Attention Deficit Hyperactivity Disorder, The NICE Guideline on Diagnosis and Management of ADHD in Children, Young People and Adults,&rdquo; National Clinical Practice Guideline Number 72, 2008:1-664. Available at www.nice.org.uk/cg072</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nissen SE, &ldquo;ADHD and Cardiovascular Risk,&rdquo; <i>N Engl J Med</i>, 2006, 354:1445-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lisdexamfetamine-drug-information/abstract-text/16549404/pubmed\" target=\"_blank\" id=\"16549404\">16549404</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Perrin JM, Friedman RA, Knilans TK; Black Box Working Group; Section on Cardiology and Cardiac Surgery. Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder. <i>Pediatrics</i>. 2008;122(2):451-453.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lisdexamfetamine-drug-information/abstract-text/18676566/pubmed\" target=\"_blank\" id=\"18676566\">18676566</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pliszka S and AACAP Work Group on Quality Issues, &ldquo;Practice Parameter for the Assessment and Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder,&rdquo; <i>J Am Acad Child Adolesc Psychiatry</i>, 2007, 46(7):894-921.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lisdexamfetamine-drug-information/abstract-text/17581453/pubmed\" target=\"_blank\" id=\"17581453\">17581453</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vetter VL, Elia J, Erickson CH, et al; American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee; American Heart Association Council on Cardiovascular Nursing. Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder [corrected]: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. <i>Circulation</i>. 2008;117(18):2407-2423.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lisdexamfetamine-drug-information/abstract-text/18427125/pubmed\" target=\"_blank\" id=\"18427125\">18427125</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vyvanse (lisdexamfetamine) [prescribing information]. Lexington, MA: Shire; January 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vyvanse (lisdexamfetamine) [product monograph]. Saint-Laurent, Quebec, Canada: Shire Canada Inc; June 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Westfall TC, Westfall DP, &ldquo;Adrenergic Agonists and Antagonists,&rdquo; <i>Goodman and Gilman's The Pharmacological Basis of Therapeutics</i>, 11th ed, Brunton LL, ed, New York, NY: McGraw-Hill, 2006, 257-8.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 10143 Version 155.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709015\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F24520558\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F10170113\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F4425750\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F6126904\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F4425789\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F49115760\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F25802880\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F25802881\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F24520559\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F4425748\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F21124159\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Controlled Substance\" href=\"#F4425744\" class=\"outlineLink\">Controlled Substance</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F7874689\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F4425790\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F4425751\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F4425741\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F4425761\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F4425757\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F4425758\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299610\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F4425767\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F4425771\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F4425753\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F4425756\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F4425792\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F4425785\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F4425774\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F5989464\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F22059480\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/10143|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=lisdexamfetamine-patient-drug-information\" class=\"drug drug_patient\">Lisdexamfetamine: Patient drug information</a></li><li><a href=\"topic.htm?path=lisdexamfetamine-pediatric-drug-information\" class=\"drug drug_pediatric\">Lisdexamfetamine: Pediatric drug information</a></li></ul></div></div>","javascript":null}